Aura Biosciences, Inc.
NASDAQ:AURABiotechnology
-$0.09 today
- Market cap
- $743.09M
- Beta
- 0.39
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$1.67
Volume 0.69M
Average 0.52M
AURA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Aura Biosciences, Inc.NASDAQ: AURA
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 121.8% from a year ago
Cash & equivalents stood at $84.79M at the end of Q1 FY2026, up 121.8% from a year earlier and up 42.5% from the prior quarter. Over 3 fiscal years it compounded at -21.2% a year.
Context
- Cash & equivalents amounted to 61.6% of total assets at the end of Q1 FY2026, up 37.0 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +121.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 59.52M USD
- Year-over-year change
- +87.8%
- 4-year CAGR
- -20.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 59.52M | +87.8% |
| FY2024 | 2024-12-31 | 31.69M | -22.8% |
| FY2023 | 2023-12-31 | 41.06M | -66.2% |
| FY2022 | 2022-12-31 | 121.58M | -18.4% |
| FY2021 | 2021-12-31 | 149.06M | — |
Cash & Equivalents vs competitors
How AURA compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +121.8% is the highest of 10, against a peer median of -15.7%.
- Cash & equivalents amounts to 61.6% of total assets for AURA, versus a peer median of 33.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $559.47M USD | -29.4% | +22.8% | 85.8% | |
| Mar 2026 | $371.63M USD | — | -33.5% | 64.4% | |
| Sep 2026 | $212.84M USD | -21.9% | +218.0% | 42.1% | |
| Mar 2026 | $84.79M USD | +121.8% | -21.2% | 61.6% | |
| Mar 2026 | $77.71M USD | -8.7% | +2.1% | 27.0% | |
| Mar 2026 | $66.52M USD | -54.3% | -19.3% | 30.5% | |
| Mar 2026 | CHF 64.37M CHF | +7.5% | +60.2% | 26.5% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | $34.79M USD | -84.7% | -1.3% | 27.3% |
| Mar 2026 | $31.86M USD | -15.7% | -37.9% | 56.0% | |
| Mar 2026 | $26.05M USD | +37.8% | +18.8% | 18.0% | |
| Mar 2026 | $7.75M USD | +2.5% | -22.5% | 35.4% | |
| Peer median (excluding AURA) | — | -15.7% | +0.4% | 33.0% | |
Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 149.06M | 121.58M | 41.06M | 31.69M | 59.52M |
| Short-term Investments | 0 | 67.23M | 185.09M | 119.4M | 84.73M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 89K | 5.72M | 3.83M | 1.83M | 1.18M |
| Total Current Assets | 153.7M | 196.7M | 231.79M | 160.62M | 149.74M |
| Property, Plant & Equipment (Net) | 6.2M | 26.04M | 22M | 20.59M | 18.45M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 768K | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 125K | 423K | 1.28M | 1.29M | 1.24M |
| Total Non-current Assets | 6.33M | 27.23M | 23.28M | 21.88M | 19.69M |
| Total Assets | 160.03M | 223.94M | 255.08M | 182.5M | 169.43M |
| Account Payables | 2.4M | 2.92M | 1.79M | 2.3M | 1.55M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.65M | 3.03M | 935K | 618K | 6.25M |
| Total Current Liabilities | 7.36M | 10.46M | 12.36M | 14.91M | 18.38M |
| Long-term Debt | 0 | 0 | 0 | 0 | 14.13M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 360K | 17.9M | 16.87M | 15.62M | 14.13M |
| Total Liabilities | 7.72M | 28.35M | 29.23M | 30.53M | 32.52M |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (152.14M) | (210.9M) | (287.31M) | (374.23M) | (480.42M) |
| Accumulated OCI | 0 | (72K) | 539K | 263K | (102K) |
| Other Stockholders Equity | 0 | 0 | 1K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 152.32M | 195.58M | 225.85M | 151.97M | 136.91M |
| Total Debt | 975K | 20.86M | 19.56M | 18.77M | 17.38M |
| Net Debt | (148.09M) | (100.72M) | (21.51M) | (12.92M) | (42.14M) |
Aura Biosciences, Inc.
NASDAQ:AURA
Intrinsic Alpha fair value
Locked
Current Price
$7.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.